1 citations
,
September 2021 in “Cureus” The rs1128977 gene variant may affect cholesterol and body measurements.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
3 citations
,
October 2011 The updated criteria improve the accuracy of diagnosing lupus.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine may be effective for treating ashy dermatosis.
January 2022 in “Gastro Hep advances” Prednisone treatment helped a woman with Cronkhite-Canada syndrome recover from hair loss and digestive issues.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
10 citations
,
August 2002 in “British Journal of Ophthalmology” Surgical excision is the best treatment for SCC, but intralesional cidofovir might be a good alternative.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
February 2024 in “International Journal of Dermatology” Cryptococcoid Sweet syndrome can be linked to hydralazine use and multiple autoantibodies, requiring high clinical suspicion and more research.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
6 citations
,
November 1996 in “Archives of Dermatology” G-CSF effectively treated a teenager's cyclic neutropenia and reduced her symptoms without adverse effects.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
June 2017 in “The Medical Journal of Australia” The man's rash, hair loss, and vision issues were due to syphilis, not CMV.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
April 2014 in “Investigative Ophthalmology & Visual Science”
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral minoxidil can potentially increase hair growth in people suffering from Central Centrifugal Cicatricial Alopecia.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
3 citations
,
November 2023 in “Journal of Investigative Dermatology” Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
15 citations
,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
27 citations
,
August 2010 in “Clinics in Dermatology” Hepatitis C virus can cause skin diseases and dermatologists play a crucial role in identifying these conditions.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
21 citations
,
March 2015 in “Neurological Sciences” A new genetic mutation linked to CARASIL syndrome and small artery disease was found in a Chinese family.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
1 citations
,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
27 citations
,
May 2016 in “Integrative Cancer Therapies” Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.
1 citations
,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.